ECM-Affinity Anti-Inflammatory Peptides for Targeted Tissue Retention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for inflammatory and autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease, do not effectively target inflamed tissues due to rapid clearance, leading to systemic side effects and incomplete cure rates.
Innovation Solution
Engineering anti-inflammatory agents with collagen-binding peptides (CBP) and vWF A3 to achieve targeted therapy by linking them to extracellular matrix (ECM)-affinity peptides, allowing for efficient delivery to inflamed tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-inflammatory therapies are administered systemically, then they provide broad immunosuppression, but they cause significant systemic side effects and do not effectively target inflamed tissues
Solution Approach 1:
The patent applies local quality by modifying anti-inflammatory agents with collagen-binding peptides (CBP) and vWF A3 domains to enable selective accumulation in inflamed tissues. This creates tissue-specific therapeutic activity while reducing systemic exposure, thereby maintaining therapeutic effectiveness while minimizing systemic side effects through localized action at the inflamed site
Solution Approach 2:
The patent uses ECM-affinity peptides as intermediary molecules that bridge the anti-inflammatory agent and the inflamed tissue. These peptides act as carriers or mediators that facilitate targeted delivery of the therapeutic agent to the extracellular matrix in inflamed areas, enabling selective targeting without direct systemic immunosuppression
2Productivity
If anti-inflammatory agents are administered without targeting modifications, then they are easy to administer, but they are rapidly cleared from inflamed tissues and require higher doses
Solution Approach 1:
The patent applies parameter changes by modifying the molecular properties of anti-inflammatory agents through conjugation with collagen-binding peptides and vWF A3 domains. This changes the pharmacokinetic parameters of the agents, enabling them to bind to the extracellular matrix in inflamed tissues and be retained there, thereby improving therapeutic efficiency and reducing the required dose through enhanced tissue retention
Solution Approach 2:
The patent applies preliminary action by pre-modifying anti-inflammatory agents with ECM-affinity peptides before administration. This preliminary modification ensures that the agents are pre-equipped to bind to and accumulate in inflamed tissues upon administration, eliminating the need for higher doses to achieve sufficient tissue concentration
3Reliability
If anti-inflammatory agents are modified with ECM-affinity peptides, then they achieve targeted delivery to inflamed tissues, but the modification process increases complexity
Solution Approach 1:
The patent applies merging by combining the anti-inflammatory agent with ECM-affinity peptides and vWF A3 domains into a single conjugated molecule. This merging of functional elements (therapeutic activity + targeting capability) achieves targeted delivery while managing complexity through integrated molecular design rather than separate components
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ECM-affinity peptides enhance the therapeutic effect of anti-inflammatory agents, reducing the required dose by up to 70% while effectively targeting and treating inflammatory conditions like inflammatory bowel disease, multiple sclerosis, and arthritis.
Implementation Method 1
anti-inflammatory agents using collagen-binding peptide (CBP) and vWF A3 to achieve targeted therapy for inflammatory diseases
Data Source
AI summary
The disclosure relates to the engineering of collagen-binding modification of anti-inflammatory agents using collagen-binding peptide (CBP) and vWF A3 to achieve targeted therapy for inflammatory diseases. Accordingly, embodiments of the disclosure relate to a composition comprising an anti-inflammatory agent operatively linked to an extracellular matrix (ECM)-affinity peptide. Also disclosed are cytokines and anti-inflammatory agents, such as CD200, linked to a serum protein and/or an ECM-affinity peptide. Further aspects of the disclosure relate to a method for treating an autoimmune or inflammatory condition in a subject comprising administering a composition of the disclosure to the subject.